Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interleukin 21

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Interleukin 21. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-003095-12 Sponsor Protocol Number: LPP17630-C-018 Start Date*: 2019-08-16
    Sponsor Name:PROGE FARM SRL
    Full Title: An investigator-blinded, active controlled, randomized, two parallel group, multi-dose clinical trial to prove the non-inferior efficacy of Lactobacillus plantarum P 17630 100.000.000 CFU soft vagi...
    Medical condition: Patients with clinically symptomatic vulvovaginal candidiasis. The following symptoms will be evaluated: pruritus, discharge, pain, dryness will be done using a daily VAS scale.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-005717-36 Sponsor Protocol Number: 1645-CI-057 Start Date*: 2012-06-14
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: Extremely low gestational age neonates randomly an assigned to be blindly resuscitated with 21% vs. 60% oxygen: influence upon mortality and chronic conditions in the neonatal period.
    Medical condition: Preterm infants aged 30 weeks or less, who need resuscitation / stabilization maneuvers with positive pressure ventilation immediately after birth
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005796-10 Sponsor Protocol Number: Start Date*: 2009-04-09
    Sponsor Name:St. Joseph-Hospital g GmbH
    Full Title: Untersuchung zum Effekt einer antibiotischen Therapie mit einem Chinolon der 4. Generation (Moxifloxacin) auf Metalloprotease 9 und Interleukin 6 im Wundsekret bei Patienten mit einem diabetischem ...
    Medical condition: Patienten mit einem Diabetes mellitus (Typ-1 und Typ-2) und einem infizierten diabetischen Fußsyndrom.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003858-33 Sponsor Protocol Number: AM0010-301 Start Date*: 2017-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi...
    Medical condition: Advanced Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015936-14 Sponsor Protocol Number: CH14.181021 Start Date*: 2010-03-10
    Sponsor Name:University Children´s Hospital Tübingen,
    Full Title: PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA
    Medical condition: Pediatric patients with relapsed neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021018-49 Sponsor Protocol Number: FOILED Start Date*: 2012-05-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: Fish OIL optimal dosE Determination Study
    Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040070 Septic shock PT
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001849-13 Sponsor Protocol Number: 2013/cardio3 Start Date*: 2013-07-09
    Sponsor Name:ASLTO2-Maria Vittoria Hospital Cardiology
    Full Title: AnakInRa Treatment of Recurrent Idiopathic Pericarditis
    Medical condition: idiopathic recurrent pericarditis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003597-17 Sponsor Protocol Number: FAR-NP-2014-01 Start Date*: 2014-11-17
    Sponsor Name:Josep Llop Talaveron
    Full Title: Pilot, randomized, double-blind clinical trial to determine the phytosterolaemia in hospitalized patients treated with total parenteral nutrition and gamma-glutamyltransferase alteration
    Medical condition: Adult hospitalized patients with parenteral nutrition and liver disfunction
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004871 10008641 Cholestatic liver disease LLT
    17.0 10022117 - Injury, poisoning and procedural complications 10074151 Parenteral nutrition associated liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003614-13 Sponsor Protocol Number: hzVSF_v13-0006 Start Date*: 2020-12-18
    Sponsor Name:ImmuneMed Inc.
    Full Title: Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-control...
    Medical condition: Moderate-to-severe COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003497-48 Sponsor Protocol Number: EMPATHY Start Date*: 2021-11-29
    Sponsor Name:Medical University of Warsaw
    Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005057-87 Sponsor Protocol Number: 337HNAS21016 Start Date*: 2022-06-15
    Sponsor Name:Inventiva S.A.
    Full Title: A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin...
    Medical condition: Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001264-28 Sponsor Protocol Number: P2-IMU-838-COV Start Date*: 2020-05-28
    Sponsor Name:Immunic AG
    Full Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Ca...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) RO (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-001785-29 Sponsor Protocol Number: ARIS2 Start Date*: 2016-08-15
    Sponsor Name:St. Vincent's University Hospital
    Full Title: Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002500-24 Sponsor Protocol Number: AOSD.2014.001 Start Date*: 2015-02-19
    Sponsor Name:AB2 Bio Ltd.
    Full Title: Open-label, multicenter, dose-escalating phase II study to investigate the safety, tolerability, and early signs of efficacy of subcutaneous administrations of Tadekinig alfa (IL-18BP) in patients ...
    Medical condition: Adult -onset Still’s Disease (AoSD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10064056 Still's disease adult onset PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001039-29 Sponsor Protocol Number: GO40515 Start Date*: 2019-02-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR ...
    Medical condition: B-Cell Non-Hodgkin Lymphoma (B-cell NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002279-16 Sponsor Protocol Number: EOGBM1-18 Start Date*: 2020-01-02
    Sponsor Name:Enterome
    Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe...
    Medical condition: Progressive or recurrent Glioblastoma (PG)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000550-12 Sponsor Protocol Number: 2014-PT026 Start Date*: 2014-07-23
    Sponsor Name:XBiotech Germany GmbH
    Full Title: A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy
    Medical condition: Symptomatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed) DE (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000880-34 Sponsor Protocol Number: 207489 Start Date*: 2017-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003119-22 Sponsor Protocol Number: EYP001-202 Start Date*: 2019-05-20
    Sponsor Name:ENYO Pharma SA
    Full Title: A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis with likely stage F2 to F3 fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-003985-15 Sponsor Protocol Number: APD334-301 Start Date*: 2019-06-21
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DE (Completed) LV (Completed) AT (Completed) NL (Completed) LT (Completed) PT (Completed) FR (Completed) EE (Completed) HU (Completed) DK (Completed) CZ (Completed) PL (Completed) BG (Completed) ES (Ongoing) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 12:09:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA